Under the EU Health Technology Assessment Regulation (HTAR), oncology products and Advanced Therapeutic Medicinal Products will be the first to undergo Joint Clinical Assessments, starting in January 2025. As there is often a paucity of clinical evidence available for these highly innovative treatments, the 2023 RWE4Decisions webinar series will consider the potential for use of RWD, given there is no EU-wide guidance on RWE generation or use.
Join us on 18 April for the first webinar on using RWE to demonstrate the value of cancer treatments. A keynote address will outline the EU policy context in terms of the Beating Cancer Plan. A panel including policy, clinical, patient, industry and HTA experts will then discuss the opportunities and challenges of RWE generation for cancer treatments in the EU in light of other policy developments such as the European Health Data Space and the HTAR.
PROGRAMME
15.00 Welcoming remarks and opening statement
Dr Matti Aapro, European Cancer Organisation Past President & Medical Oncologist
Karen Facey, Evidence Based Health Policy Consultant, RWE4Decisions Secretariat
15.05 Keynote presentation
15.05 Keynote
EU Mission on Cancer – Real World Evidence Contributing to Longer and Better Lives
Prof Christine Chomienne, Professor of Cellular Biology at the Université de Paris, Vice-Chair of the EU Cancer Mission
15.20 Moderated discussion
MEP Tomislav Sokol (EPP, Croatia), Co-Rapporteur of the European Health Data Space for the Committee on Environment, Public Health and Food Safety (ENVI)
Tanja Podkonjak, Director, EUCAN Oncology Access and Reimbursement Policy, Takeda
Natacha Bolaños, Head, Membership & Alliances, Lymphoma Coalition
Emma Hernlund, Analyst, Swedish Dental and Pharmaceutical Benefits Agency (TLV)
–
Q&A with the audience
–
16.20 Closing remarks
Matti Aapro, Medical oncologist, Genolier Cancer Center & Immediate Past-President, European Cancer Organisation
Karen Facey, Evidence Based Health Policy Consultant, RWE4Decisions Secretariat
16.30 Meeting close